HeartBeam Inc. (NASDAQ: BEAT) announced a collaboration with the Icahn School of Medicine at Mount Sinai to develop AI-ECG algorithms for cardiac monitoring applications. The partnership combines HeartBeam's 3D ECG signal collection technology with Mount Sinai's clinical data and artificial intelligence expertise.

The collaboration aims to create AI models using HeartBeam's synthesized 12-lead ECG data collected from patients in home settings. Mount Sinai will contribute clinically annotated 12-lead ECG data to train and validate various AI algorithms intended for deployment on HeartBeam's platform.

HeartBeam's technology captures heart electrical activity from three non-coplanar dimensions without cables, enabling 12-lead ECG data collection outside traditional clinical settings. The company received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025.

The partnership will be led by HeartBeam's AI team under Lance Myers, PhD, working with Mount Sinai researchers including Joshua Lampert, MD, Vivek Reddy, MD, and Girish Nadkarni, MD, who serves as Chief AI Officer of the Mount Sinai Health System.

"By pairing our ability to gather high-fidelity real-world ECG data with Mount Sinai's extensive clinical data resources and AI expertise, we are creating a differentiated cardiac intelligence engine," said Robert Eno, HeartBeam's chief executive officer.

The organizations plan to develop AI models for wellness insights, condition-focused assessments, and chronic condition management applications. The collaboration utilizes longitudinal, real-world ECG data rather than isolated clinical snapshots for algorithm development.

Mount Sinai Health System operates seven hospitals and more than 400 outpatient practices in the New York metro area, serving as one of the region's largest academic medical systems.